



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				10/775,169	
				Filing Date	
				February 11, 2004	
				First Named Inventor	
		Michael E. Burczynski et al.			
Art Unit		1631			
Examiner Name		Not Yet Assigned			
Sheet	1	of	2	Attorney Docket Number	031896-013000 (AM101080)


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ² (if known)				
		WO00/040749	07-13-00	Chin		
		WO02/040000	05-23-02	Dukart et al.		
		WO01/081916	11-01-01	Ma et al.		
		WO03/032813	04-24-03	Gerritsen et al.		
		WO04/072265	08-26-04	Donner et al.		
		WO04/048933	06-10-04	Stover et al.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		BURCZYNSKI et al., "Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood", <i>European Journal of Cancer</i> , Pergamon Press, Oxford, GB, Vol. 38, November 2002, page S51		
		SCHULZE-KOOPS, H., et al., "Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)," <i>Clinical and Experimental Immunology</i> , Vol. 106, No. 2, November 1996, pages 190-196		
		DIPAOLA, R. S., et al., "Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies," <i>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</i> , Vol. 17, No. 7, July 1999, pages 2213-2218		
		"Product Catalogue", <i>Affymetrix</i> , January 2002, page 1		
		SU, A. I., et al., "Molecular classification of human carcinomas by use of gene expression signatures", <i>Cancer Research</i> , Vol. No. 20, October 15, 2001, pages 7388-7393		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/775,169
				Filing Date	February 11, 2004
				First Named Inventor	Michael E. Burczynski et al.
				Art Unit	1631
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	031896-013000 (AM101080)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ELIT, LAURIE, "CCI-779 Wyeth", <i>Current Opinion in Investigational Drugs</i> , Vol. 3, No. 8, August 2002, pages 1249-1253	
		RINIGER, J. A. et al., "Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity", <i>Drug Discovery Today</i> , Vol. 5, No. 12, December 1, 2000, pages 560-568	
		PERALBA, JOSEP MARIA et al., "Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients", <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 9, No. 8, August 1, 2003, pages 2887-2892	
		SU, ANDREW I., et al., "Large-scale analysis of the human and mouse transcriptomes," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , Vol. 99, No. 7, April 2, 2002, pages 4465-4470	
		PCT International Search Report; PCT/US2004/006601; November 19, 2004; 4 pages	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Docket No. 031896-013000 (AM 101080)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT application of:

Michael Burczynski *et al.*

Group Art Unit: 1631

Application No.: 10/775,169

Examiner: Not Yet Assigned

Filed: February 11, 2004

For: METHODS FOR MONITORING DRUG ACTIVITIES IN VIVO

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

By:


A handwritten signature in black ink, appearing to read "Ray Van Dyke", written over a horizontal line.

Raymond Van Dyke
Registration No. 34,746

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128

Telephone: (202) 585-8000

Date: February 15, 2005



IFW

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/775,169	
	Filing Date	February 11, 2004	
	First Named Inventor	Michael E. BURCZYNSKI, et al.	
	Group Art Unit	1631	
	Examiner Name	N/A	
Total Number of Pages in This Submission		Attorney Docket Number	031896-013000 (AM 101080)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Other Enclosure(s): Copies of references
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (740819-383) for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	<u>Raymond Van Dyke, Reg. No. 34,746</u> Nixon Peabody LLP 409 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	February 15, 2005

CERTIFICATE OF MAILING	
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 703-746-4060.	
Date	Signature